MedTrace Logo

Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

NCT01412021 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 375

Last updated 2019-08-08

Study results available
· View outcomes & findings →

Summary

This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug:

* Unknown adverse drug reactions (especially important adverse drug reactions)
* Incidence and conditions of occurrence of adverse reactions in the clinical setting
* Factors that may affect the safety and effectiveness of Humira

Conditions

  • Arthritis, Juvenile Rheumatoid

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-01
Primary Completion
2018-04-02
Completion
2018-04-02

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01412021 on ClinicalTrials.gov